Sign In
Buy VRTX
$441.74
+13.40 (+3.13%)
At Close: Jun 04, 2026
Vertex Pharmaceuticals Incorporated (VRTX) Q4 2023 Earnings Call Transcript
08:49pm, Monday, 05'th Feb 2024
Vertex Pharmaceuticals Incorporated (VRTX) Q4 2023 Earnings Call Transcript
Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Top Estimates
06:21pm, Monday, 05'th Feb 2024
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.20 per share, beating the Zacks Consensus Estimate of $4.10 per share. This compares to earnings of $3.76 per share a year ago.
PLTR, VRTX, NXPI Earnings Just Released
05:40pm, Monday, 05'th Feb 2024
Palantir's (PLTR) 4Q adjusted EPS came in at $0.08 versus an estimated $0.08 and revenue came in at $602.41M versus an estimated $603.48M. Vertex Pharmaceuticals' (VRTX) 4Q adjusted EPS came in at $4.
Vertex's triple combination CF drug meets main late-stage trial goals
04:18pm, Monday, 05'th Feb 2024
Vertex Pharmaceuticals experimental triple combination cystic fibrosis (CF) treatment met all late-stage study goals when tested in patients aged 12 years and older, the company said on Monday.
Vertex Pharmaceuticals May Be About to Solve a Common Health Problem. Is the Stock a Buy?
04:12pm, Friday, 02'nd Feb 2024
Vertex's cystic fibrosis portfolio has been a raging success for the company. The biotech's next potential product addresses the extremely common problem of pain -- and could become its next blockbust
Top Stock Picks 2024: 3 Healthcare Stocks Leading Medical Advancements
09:10pm, Thursday, 01'st Feb 2024
Healthcare stocks are one part of the stock market that has a lot of room to grow until 2024. The healthcare industry is growing because of the growing focus on health and well-being around the world
Buy Alert: 3 Stocks Sitting in the Sweet Spot
04:25pm, Wednesday, 31'st Jan 2024
An investment sweet spot is often informally defined as the ideal entry point for buying based on recent macroeconomic developments. Technically, it's a price entry point that guarantees maximum profi
Vertex's (VRTX) Non-Opioid Pain Drug Meets Primary Goal
01:20pm, Wednesday, 31'st Jan 2024
Three late-stage studies data show that Vertex's (VRTX) experimental non-opioid drug reduced pain across a 48-hour period. Based on this data, VRTX intends to submit an FDA filing by mid-2024.
Stay Ahead of the Game With Vertex (VRTX) Q4 Earnings: Wall Street's Insights on Key Metrics
10:20am, Wednesday, 31'st Jan 2024
Beyond analysts' top -and-bottom-line estimates for Vertex (VRTX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter
Why Vertex Pharmaceuticals Stock Topped the Market Today
07:10pm, Tuesday, 30'th Jan 2024
The big biotech might just have a winner on its hands with an investigational pain treatment. VX-548 performed well in late-stage clinical testing, although there were some caveats.
Vertex non-opioid painkiller shows positive results in critical late-stage trial on acute pain
04:31pm, Tuesday, 30'th Jan 2024
The trial results bring the biotech company one step closer to developing a drug that can provide strong pain relief without the addictive potential of opioids.
Vertex Pharmaceuticals (VRTX) Laps the Stock Market: Here's Why
06:56pm, Monday, 29'th Jan 2024
Vertex Pharmaceuticals (VRTX) closed at $435.82 in the latest trading session, marking a +1.31% move from the prior day.
Here's My Top Growth Stock to Buy Right Now
11:50am, Saturday, 27'th Jan 2024
This stock is already highly profitable with a huge cash stockpile thanks to a monopoly in its core niche market. It offers tremendous growth potential with multiple near-term catalysts.
Where Will Vertex Pharmaceuticals Be in 10 Years?
12:00pm, Thursday, 25'th Jan 2024
Vertex Pharmaceuticals' work in cystic fibrosis isn't done yet. The company also stands to make headway in other areas over time.
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
09:45am, Thursday, 25'th Jan 2024
Sarepta Therapeutics and Vertex Pharmaceuticals both go after rare diseases. Sarepta has made headway in its core area, but there is more work to be done.
